Summary
This multi-centre, multi-laboratory study examined the prognostic utility of FGFR3 mutation status versus P53 and KI-67 expression in 1058 patients with invasive bladder cancer treated by radical cystectomy. As suggested by the title and study design, the authors sought to determine which molecular and immunohistochemical markers most reliably predict patient outcomes and may guide treatment stratification. The findings contribute to the growing body of evidence on bladder cancer tumour biology and prognostication, though specific outcome associations are not disclosed in the available metadata.
UK applicability
Findings on molecular prognostic markers in bladder cancer are directly applicable to UK urological oncology practice and may inform stratification and follow-up protocols in the NHS. Multi-centre standardisation of FGFR3, P53, and KI-67 testing—as addressed in this study—is relevant to establishing consistent prognostic frameworks across UK cancer centres.
Key measures
FGFR3 mutation status, P53 expression levels, KI-67 proliferation index, clinical outcomes following radical cystectomy (recurrence, progression, survival)
Outcomes reported
The study evaluated the prognostic value of FGFR3 mutation status, P53 expression, and KI-67 expression as predictive markers for outcomes in patients with invasive bladder cancer treated by radical cystectomy. The analysis involved 1058 patients across multiple centres and laboratories to assess the independent and combined prognostic significance of these molecular and immunohistochemical markers.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.